UK-BASED pSivida subsidiary pSiMedica has received notice of allowance of a new US patent.
The patent contains two main claims – a method of implanting an electronic device within a living animal or human body wherein the device includes bioactive silicon; and a method of delivering a drug to a living animal or human by placing the drug to be delivered on or within a bioactive silicon structure.
pSivida managing director Gavin Rezos said the new patent would further draw attention in the US to the versatility of the BioSilicon technology platform.